TICKERNOMICS Sign up
Last Update: 2024-12-27 15:28:13
BeyondSpring Inc. ( BYSI ) https://www.beyondspringpharma.com
1.66USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
BYSI
89.15%
SPY
32.66%
-63.10%
BYSI
SPY
108.59%
-89.54%
BYSI
SPY
302.52%
BYSI
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
66.03
51.67
0.01
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-3.71
35.21
-2.51
0.00
0.00
-3.55
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-742.20
100.00
-727.10
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
5.9392
-52.91
-53.28
0.44
Other Earnings and Cash Flow Stats:
BeyondSpring Inc. ( BYSI ) Net Income TTM ($MM) is -17.77
BeyondSpring Inc. ( BYSI ) Operating Income TTM ($MM) is -18.98
BeyondSpring Inc. ( BYSI ) Owners' Earnings Annual ($MM) is 0.00
BeyondSpring Inc. ( BYSI ) Current Price to Owners' Earnings ratio is 0.00
BeyondSpring Inc. ( BYSI ) EBITDA TTM ($MM) is -18.71
BeyondSpring Inc. ( BYSI ) EBITDA Margin is -727.10%
Capital Allocation:
BeyondSpring Inc. ( BYSI ) has paid 0.00 dividends per share and bought back -0.054828999999998 million shares in the past 12 months
BeyondSpring Inc. ( BYSI ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
BeyondSpring Inc. ( BYSI ) Interest-bearing Debt ($MM) as of last quarter is 0
BeyondSpring Inc. ( BYSI ) Annual Working Capital Investments ($MM) are 10
BeyondSpring Inc. ( BYSI ) Book Value ($MM) as of last quarter is -27
BeyondSpring Inc. ( BYSI ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
BeyondSpring Inc. ( BYSI ) has 8 million in cash on hand as of last quarter
BeyondSpring Inc. ( BYSI ) has 8 million of liabilities due within 12 months, and long term debt 0 as of last quarter
BeyondSpring Inc. ( BYSI ) has 39 common shares outstanding as of last quarter
BeyondSpring Inc. ( BYSI ) has 0 million USD of preferred stock value
Academic Scores:
BeyondSpring Inc. ( BYSI ) Altman Z-Score is -28.06 as of last quarter
BeyondSpring Inc. ( BYSI ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
BeyondSpring Inc. ( BYSI ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of BeyondSpring Inc. ( BYSI ) for the amount of $ on
25.54% of BeyondSpring Inc. ( BYSI ) is held by insiders, and 13.79% is held by institutions
BeyondSpring Inc. ( BYSI ) went public on 2017-03-09
Other BeyondSpring Inc. ( BYSI ) financial metrics:
FCF:0.00
Unlevered Free Cash Flow:-33.97
EPS:-0.37
Operating Margin:-742.20
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:48.12
Beta:0.44
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About BeyondSpring Inc. ( BYSI ) :
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.